Maria Raad-Sarabia , Maria Cardona-Blanco , Carmen Mendoza-Paternina , José Correa-Guerrero , Jorge Rico-Fontalvo , Rodrigo Daza-Arnedo , Zulay Mondol-Almeida , Jhonny Llinas-Rincon , Liseth Sierra-Torres , Juan Marrugo-Yunda
{"title":"口服抗糖尿病药与抑郁障碍:风险还是保护?","authors":"Maria Raad-Sarabia , Maria Cardona-Blanco , Carmen Mendoza-Paternina , José Correa-Guerrero , Jorge Rico-Fontalvo , Rodrigo Daza-Arnedo , Zulay Mondol-Almeida , Jhonny Llinas-Rincon , Liseth Sierra-Torres , Juan Marrugo-Yunda","doi":"10.1016/j.psiq.2024.100441","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Diabetes mellitus and mood disorders are two entities that are intertwined with common pathophysiological mechanisms. Oral hypoglycemic agents are a fundamental pillar in obtaining adequate glucose control in diabetic individuals and, recently, the high prevalence of these two pathologies in the same patient have led clinical studies to focus on analyzing the effect of oral hypoglycemic agents in diabetics. patients with type 2 diabetes mellitus and depressive disorder.</p></div><div><h3>Objective</h3><p>To carry out a review of the available literature on hypoglycemic medication in the context of patients with diabetes mellitus and depressive disorder.</p></div><div><h3>Conclusions</h3><p>Although oral antidiabetics have been shown to have an antidepressant effect in certain experimental models, in clinical practice the evidence is scarce, but the lower risk of depression with certain antidiabetics is particularly noteworthy, leaving open the possibilities of future studies with the adequate nature that allows clarifying the effect of oral hypoglycemic agents in the population with diabetes mellitus and depressive disorder.</p></div>","PeriodicalId":39337,"journal":{"name":"Psiquiatria Biologica","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Antidiabéticos orales y trastornos depresivos: ¿riesgo o protección?\",\"authors\":\"Maria Raad-Sarabia , Maria Cardona-Blanco , Carmen Mendoza-Paternina , José Correa-Guerrero , Jorge Rico-Fontalvo , Rodrigo Daza-Arnedo , Zulay Mondol-Almeida , Jhonny Llinas-Rincon , Liseth Sierra-Torres , Juan Marrugo-Yunda\",\"doi\":\"10.1016/j.psiq.2024.100441\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><p>Diabetes mellitus and mood disorders are two entities that are intertwined with common pathophysiological mechanisms. Oral hypoglycemic agents are a fundamental pillar in obtaining adequate glucose control in diabetic individuals and, recently, the high prevalence of these two pathologies in the same patient have led clinical studies to focus on analyzing the effect of oral hypoglycemic agents in diabetics. patients with type 2 diabetes mellitus and depressive disorder.</p></div><div><h3>Objective</h3><p>To carry out a review of the available literature on hypoglycemic medication in the context of patients with diabetes mellitus and depressive disorder.</p></div><div><h3>Conclusions</h3><p>Although oral antidiabetics have been shown to have an antidepressant effect in certain experimental models, in clinical practice the evidence is scarce, but the lower risk of depression with certain antidiabetics is particularly noteworthy, leaving open the possibilities of future studies with the adequate nature that allows clarifying the effect of oral hypoglycemic agents in the population with diabetes mellitus and depressive disorder.</p></div>\",\"PeriodicalId\":39337,\"journal\":{\"name\":\"Psiquiatria Biologica\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Psiquiatria Biologica\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1134593424000010\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psiquiatria Biologica","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1134593424000010","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
Antidiabéticos orales y trastornos depresivos: ¿riesgo o protección?
Introduction
Diabetes mellitus and mood disorders are two entities that are intertwined with common pathophysiological mechanisms. Oral hypoglycemic agents are a fundamental pillar in obtaining adequate glucose control in diabetic individuals and, recently, the high prevalence of these two pathologies in the same patient have led clinical studies to focus on analyzing the effect of oral hypoglycemic agents in diabetics. patients with type 2 diabetes mellitus and depressive disorder.
Objective
To carry out a review of the available literature on hypoglycemic medication in the context of patients with diabetes mellitus and depressive disorder.
Conclusions
Although oral antidiabetics have been shown to have an antidepressant effect in certain experimental models, in clinical practice the evidence is scarce, but the lower risk of depression with certain antidiabetics is particularly noteworthy, leaving open the possibilities of future studies with the adequate nature that allows clarifying the effect of oral hypoglycemic agents in the population with diabetes mellitus and depressive disorder.
期刊介绍:
Es la Publicación Oficial de la Sociedad Española de Psiquiatría Biológica. Los recientes avances en el conocimiento de la bioquímica y de la fisiología cerebrales y el progreso en general en el campo de las neurociencias han abierto el camino al desarrollo de la psiquiatría biológica, fundada sobre bases anatomofisiológicas, más sólidas y científicas que la psiquiatría tradicional.